IPO
4BIO Capital, an international venture capital firm focused solely on the advanced therapies sector, announces its investment in Redpin Therapeutics, Inc., a pioneering chemogenetics company developing drug-controlled gene therapies to address intractable diseases of the nervous system.
Heidelberg Pharma AG published its financial results and annual report for fiscal year 2019 and its outlook for 2020.
Priority Review for BLA submission was granted by U.S. FDA for tafasitamab in combination with lenalidomide for relapsed/refractory diffuse large B cell lymphoma (r/r DLBCL) based on positive primary analysis data of L-MIND and Re-MIND studies
The company has nine drug candidates in human clinical trials.
Consumer healthcare company HRA Pharma grew their total group revenues by 20.8% in 2019 with EBITDA growing by 30%
Numab Therapeutics announced the closing of its Series B financing round at a total volume of CHF 22M. New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella.
Polarean Imaging plc announces that it has issued 232,010 new ordinary shares of £0.00037 each in the capital of the Company at par value, following the exercise of warrants by Amphion Innovations plc.
The company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expected.
4basebio AG announces the allotment ratio and the final number of shares for the announced share buyback program.
Montis Biosciences launched with €8,4 million seed financing and a novel approach to immune-oncology
Montis Biosciences announces its launch with €8,4 million in seed financing from an international investor syndicate to investigate interactions between perivascular macrophages and tumor vasculature.
PRESS RELEASES